These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937 [TBL] [Abstract][Full Text] [Related]
3. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031 [TBL] [Abstract][Full Text] [Related]
5. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243 [TBL] [Abstract][Full Text] [Related]
6. The Genetic Duet of Liu J; Liu R; Shen X; Zhu G; Li B; Xing M J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570 [No Abstract] [Full Text] [Related]
7. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes. Simões-Pereira J; Saramago A; Rodrigues R; Pojo M; Pires C; Horta M; López-Presa D; Rito M; Cabrera R; Ferreira TC; Leite V; Cavaco BM Endocrine; 2024 May; 84(2):625-634. PubMed ID: 38102497 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Hong DS; Drilon A; Wirth LJ Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725 [TBL] [Abstract][Full Text] [Related]
12. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953 [No Abstract] [Full Text] [Related]
13. Clinical characteristics and treatment patterns of patients with Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641 [TBL] [Abstract][Full Text] [Related]
15. Risk Stratification Using a Novel Genetic Classifier Including Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836 [No Abstract] [Full Text] [Related]
16. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518 [TBL] [Abstract][Full Text] [Related]
17. Effect of BRAF Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787 [TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer. Tan G; Jin B; Qian X; Wang Y; Zhang G; Agyekum EA; Wang F; Shi L; Zhang Y; Mao Z; Shi C; Xu Y; Li X; Zhang L; Li S Sci Rep; 2024 Oct; 14(1):23719. PubMed ID: 39390090 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis. Okubo Y; Toda S; Kadoya M; Sato S; Yoshioka E; Hasegawa C; Ono K; Washimi K; Yokose T; Miyagi Y; Masudo K; Iwasaki H; Hayashi H Virchows Arch; 2024 Sep; 485(3):509-518. PubMed ID: 38472412 [TBL] [Abstract][Full Text] [Related]
20. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Leeman-Neill RJ; Kelly LM; Liu P; Brenner AV; Little MP; Bogdanova TI; Evdokimova VN; Hatch M; Zurnadzy LY; Nikiforova MN; Yue NJ; Zhang M; Mabuchi K; Tronko MD; Nikiforov YE Cancer; 2014 Mar; 120(6):799-807. PubMed ID: 24327398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]